• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Truist initiated coverage on AbCellera Biologics with a new price target

    11/16/22 7:18:52 AM ET
    $ABCL
    Pharmaceuticals and Biotechnology
    Health Care
    Get the next $ABCL alert in real time by email
    Truist initiated coverage of AbCellera Biologics with a rating of Buy and set a new price target of $29.00
    Get the next $ABCL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABCL

    DatePrice TargetRatingAnalyst
    8/20/2024Buy → Hold
    The Benchmark Company
    2/22/2024$9.00Hold → Buy
    The Benchmark Company
    12/5/2023$6.00Overweight
    KeyBanc Capital Markets
    11/6/2023Buy → Hold
    The Benchmark Company
    10/13/2023$20.00Overweight
    Piper Sandler
    2/28/2023Outperform
    Cowen
    12/15/2022$30.00Buy
    Goldman
    11/16/2022$29.00Buy
    Truist
    More analyst ratings

    $ABCL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • AbCellera Biologics downgraded by The Benchmark Company

      The Benchmark Company downgraded AbCellera Biologics from Buy to Hold

      8/20/24 6:47:45 AM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • AbCellera Biologics upgraded by The Benchmark Company with a new price target

      The Benchmark Company upgraded AbCellera Biologics from Hold to Buy and set a new price target of $9.00

      2/22/24 6:35:00 AM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • KeyBanc Capital Markets initiated coverage on AbCellera Biologics with a new price target

      KeyBanc Capital Markets initiated coverage of AbCellera Biologics with a rating of Overweight and set a new price target of $6.00

      12/5/23 7:12:21 AM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care

    $ABCL
    Leadership Updates

    Live Leadership Updates

    See more
    • AbCellera Announces Resignation of Board Member

      AbCellera (NASDAQ:ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company's Board of Directors for personal reasons, effective March 7, 2024. "AbCellera continues to expand the frontier of biotech, a nefariously difficult and vital field," said Peter Thiel. "I am proud to have helped them with their mission." Mr. Thiel joined AbCellera's Board of Directors in November 2020 and served as the Chairman of the Company's Nominating and Corporate Governance Committee. Effective March 7, 2024, Dr. Andrew Lo, a member of the Company's Board of Directors, will be appointed to the Nominating and Corporate Governance Committee of the Board of Dir

      2/23/24 4:30:00 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • DAMONA Pharmaceuticals Appoints John Reilly as Chief Executive Officer

      TORONTO, June 13, 2023 /PRNewswire/ -- DAMONA Pharmaceuticals, a preclinical biopharmaceutical company focused on the discovery and development of first-in-class small molecules for the treatment and prevention of cognitive symptoms associated with brain disorders and aging, today announced the appointment of John Reilly as the company's Chief Executive Officer and member of the Board of Directors. Mr. Reilly brings two decades of leadership experience building and creating value for biotechnology companies, with deep knowledge and expertise in corporate strategy, business dev

      6/13/23 7:59:57 AM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • AbCellera Announces Changes to Its Board of Directors

      AbCellera (NASDAQ:ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced changes to its Board of Directors with the appointment of Andrew W. Lo, Ph.D., as an independent director and the resignation of John Hamer, Ph.D. Changes are effective immediately. Dr. Lo has developed new financial engineering tools and business models for drug and device development and healthcare delivery, statistical methods for incorporating patient preferences into the drug approval process, and machine-learning for predicting clinical trial outcomes. He will serve on the Audit and Compensation Committees of the Board of Directors. "Andrew is a d

      12/7/21 9:00:00 AM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care